Final Post-Marketing Surveillance (PMS) Report for Selected Human Medicines Circulating in South Africa 2023/2026 - SAHPRA

Final Post-Marketing Surveillance (PMS) Report for Selected Human Medicines Circulating in South Africa 2023/2026

Final Post-Marketing Surveillance (PMS) Report for Selected Human Medicines Circulating in South Africa 2023/2026

All regulatory systems recognise the importance of quality medicines. Several factors may lead to medicines not fully complying with quality requirements and specifications. Those factors may include manufacturing processes, transportation, storage, distribution, handling, and dispensing to patients. During the period of development, medicines are tested for short-term safety and efficacy over a limited time duration in a limited number of carefully selected individuals who have been “controlled” for this purpose. Therefore, there are possible risks after medicines have been released onto the market, resulting in adverse effects on the population, since medicines are then used in real-life scenarios as opposed to highly controlled pre-marketing trials

Download latest version
Document Number: OF-RC-INSP-09E
Version: 1
Date Updated: 16/11/2026
File Type: www
Category: Reports
Unit: Regulatory Compliance